[go: up one dir, main page]

HU9203698D0 - Method for producing crystallic salts of 9,9-alkylene-3,7-diaza-bicyclononane compounds with fumaric aicd - Google Patents

Method for producing crystallic salts of 9,9-alkylene-3,7-diaza-bicyclononane compounds with fumaric aicd

Info

Publication number
HU9203698D0
HU9203698D0 HU9203698A HU369892A HU9203698D0 HU 9203698 D0 HU9203698 D0 HU 9203698D0 HU 9203698 A HU9203698 A HU 9203698A HU 369892 A HU369892 A HU 369892A HU 9203698 D0 HU9203698 D0 HU 9203698D0
Authority
HU
Hungary
Prior art keywords
salts
alkylene
fumaric
crystallic
bicyclononane
Prior art date
Application number
HU9203698A
Other languages
English (en)
Inventor
Uwe Schoen
Walter Heitmann
Uwe Matzel
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Publication of HU9203698D0 publication Critical patent/HU9203698D0/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9203698A 1991-12-03 1992-11-25 Method for producing crystallic salts of 9,9-alkylene-3,7-diaza-bicyclononane compounds with fumaric aicd HU9203698D0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4139763A DE4139763A1 (de) 1991-12-03 1991-12-03 Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
HU9203698D0 true HU9203698D0 (en) 1993-03-29

Family

ID=6446125

Family Applications (3)

Application Number Title Priority Date Filing Date
HU9203698A HU213672B (en) 1991-12-03 1992-11-25 Process for producing fumaric acid salts of 9,9-alkylen-3,7-diaza-bicyclononan-compounds and medicaments containing the same
HU9203698A HU9203698D0 (en) 1991-12-03 1992-11-25 Method for producing crystallic salts of 9,9-alkylene-3,7-diaza-bicyclononane compounds with fumaric aicd
HU94P/P00033P HU210215A9 (en) 1991-12-03 1994-09-30 Crystalline fumaric acid salts of n,n'-disubstituted 9,9-alkylene-3,7- -diazabicyclo/3.3.1/nonane compounds and process for their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9203698A HU213672B (en) 1991-12-03 1992-11-25 Process for producing fumaric acid salts of 9,9-alkylen-3,7-diaza-bicyclononan-compounds and medicaments containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU94P/P00033P HU210215A9 (en) 1991-12-03 1994-09-30 Crystalline fumaric acid salts of n,n'-disubstituted 9,9-alkylene-3,7- -diazabicyclo/3.3.1/nonane compounds and process for their preparation

Country Status (25)

Country Link
US (1) US5324732A (hu)
EP (1) EP0550383B1 (hu)
JP (1) JP3180848B2 (hu)
KR (1) KR100252389B1 (hu)
CN (1) CN1040758C (hu)
AT (1) ATE124411T1 (hu)
AU (1) AU652869B2 (hu)
CA (1) CA2084489C (hu)
CZ (1) CZ281930B6 (hu)
DE (2) DE4139763A1 (hu)
DK (1) DK0550383T3 (hu)
DZ (1) DZ1636A1 (hu)
ES (1) ES2073900T3 (hu)
FI (1) FI100053B (hu)
HK (1) HK1006568A1 (hu)
HU (3) HU213672B (hu)
IL (1) IL103819A (hu)
LT (1) LTIP230A (hu)
MX (1) MX9206988A (hu)
NO (1) NO300687B1 (hu)
NZ (1) NZ245227A (hu)
PH (1) PH31114A (hu)
SK (1) SK332292A3 (hu)
TW (1) TW274084B (hu)
ZA (1) ZA928863B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4421324A1 (de) * 1994-06-17 1995-12-21 Kali Chemie Pharma Gmbh Neue 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen enthaltende Arzneimittel
AU2002223572B2 (en) * 2000-09-29 2005-09-08 Abbvie B.V. Ion-strength independent sustained release pharmaceutical formulation
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
CN1822833A (zh) * 2003-07-21 2006-08-23 索尔瓦药物有限公司 3,7－二氮杂双环[3,3,1]壬烷化合物在治疗和/或预防男性患者心律失常中的用途
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
WO2005030207A1 (en) * 2003-09-26 2005-04-07 Solvay Pharmaceuticals Gmbh Use of 3, 7-diazabicyclo (3.3.1) nonane compounds for the treatment of brugada syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2551283C3 (de) * 1975-11-14 1981-02-19 Hokuriku Pharmaceutical Co., Ltd., Katsuyama, Fukui (Japan) Monofumarsäuresalz von 3-Pyridylmethylnikotinat und Verfahren zu seiner Herstellung
DE2658558A1 (de) * 1976-12-23 1978-06-29 Bayer Ag Diazabicyclo(3,3,1)nonane, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3234697A1 (de) * 1982-09-18 1984-03-22 Kali-Chemie Pharma Gmbh, 3000 Hannover Neue diazabicyclo-(3,3,1)-nonane
PT88381B (pt) * 1987-09-09 1995-07-06 Kali Chemie Pharma Gmbh Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
US5324732A (en) 1994-06-28
IL103819A (en) 1996-09-12
ATE124411T1 (de) 1995-07-15
AU2981592A (en) 1993-06-10
CZ332292A3 (en) 1993-08-11
IL103819A0 (en) 1993-04-04
NO300687B1 (no) 1997-07-07
MX9206988A (es) 1993-06-01
TW274084B (hu) 1996-04-11
HU213672B (en) 1997-09-29
AU652869B2 (en) 1994-09-08
DZ1636A1 (fr) 2002-02-17
LTIP230A (en) 1994-05-15
DE59202726D1 (de) 1995-08-03
CA2084489C (en) 2002-10-08
HK1006568A1 (en) 1999-03-05
ZA928863B (en) 1993-05-13
EP0550383A1 (de) 1993-07-07
ES2073900T3 (es) 1995-08-16
NZ245227A (en) 1994-06-27
NO924647D0 (no) 1992-12-02
KR100252389B1 (ko) 2000-05-01
NO924647L (no) 1993-06-04
CA2084489A1 (en) 1993-06-04
CN1072931A (zh) 1993-06-09
PH31114A (en) 1998-02-23
FI925482A0 (fi) 1992-12-02
HUT63417A (en) 1993-08-30
EP0550383B1 (de) 1995-06-28
HU210215A9 (en) 1995-02-28
DK0550383T3 (da) 1995-08-28
SK279519B6 (sk) 1998-12-02
DE4139763A1 (de) 1993-06-09
FI925482L (fi) 1993-06-04
JPH05247040A (ja) 1993-09-24
FI100053B (fi) 1997-09-15
KR930012772A (ko) 1993-07-21
JP3180848B2 (ja) 2001-06-25
CZ281930B6 (cs) 1997-04-16
CN1040758C (zh) 1998-11-18
SK332292A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
EP0498471A3 (en) Liposomes comprising a guanidino aminoglycoside
DK0490823T3 (hu)
HU896498D0 (en) Process for preparation of low volatility salts
KR100189590B1 (en) Method for inhibiting gastric acid secretion with 8-substituted-2-amino-1,2,3,4-tetrahydronapthalene
HU9203698D0 (en) Method for producing crystallic salts of 9,9-alkylene-3,7-diaza-bicyclononane compounds with fumaric aicd
HUT45564A (en) Process for producing hirudine variants
PT84382A (en) Process for preparing substituted 1,3,4,9-tetrahydropyrano ]3,4-b" indole-1-acetic acids
PL296165A1 (en) Method of obtaining diastereoselective reducing pinacolic coupling of homochiral -aminoaldehydes
SG52396A1 (en) Process for preparing purified 2,6-naphtalenedicorboxylic acid
AU1630288A (en) Substituted compounds, processes for their preparation and uses thereof
GR3030042T3 (en) Enantiomeric pure cis-2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation
EP0548895A3 (en) Process for the preparation of pure diasteroisomers of tetrahydrofolates
HUT50476A (en) Process for producing 3-pyrrolidinyl-thio-1-azabicyclo/3,2,0/hept-2-ene-2-carboxylic acid derivatives
MA20491A1 (fr) Procede de preparation d'aminomethylene-2 indanedione-1,3 substituees sur l'azote
EP0552912A3 (en) Method for producing 2,6-dihydroxybenzoic acid
HUT38331A (en) Process for producing 5,6-dihydro-4h-cyclopenta/b/thiophene-6-carboxylic acid derivatives
HUT40432A (en) Process for producing 12b-substituted 1-/hydroxy-methyl/-oktahydro-indolo/2,3-a/quinolizin derivatives
GB9022309D0 (en) 1-azabicyclo(3.2.0.)hept-2-ene-2-carboxylic acid compounds
ZA882135B (en) Process for the preparation of 5-hydroxydiprafenone and its acid addition salts
GB8909797D0 (en) 1-azabicyclo(3.2.0.)hept-2-ene-2-carboxylic acid compounds
GB8921463D0 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
GB9022307D0 (en) 1-azabicyclo(3.2.0.)hept-2-ene-2-carboxylic acid compounds
GB9018299D0 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
GB9016507D0 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
HU209498B (en) Process for producing 1,4-diazepino/3,4-b/quinasoline-3,7-dione derivatives and pharmaceutically acceptable salts thereof